21 CFR 1271: HCT/P Scope and Applicability

21 CFR 1271 is the FDA regulatory framework for human cells, tissues, and cellular and tissue-based products, usually abbreviated HCT/Ps. Its purpose is to establish an electronic registration and listing system, donor-eligibility requirements, current good tissue practice (CGTP), and other procedures to prevent the introduction, transmission, and spread of communicable diseases through HCT/Ps.

The framework answers several different questions: whether an article is an HCT/P; whether an establishment qualifies for an exception; whether the product meets the conditions for regulation solely under section 361 of the Public Health Service Act; and which requirements apply to the establishment’s activities. These questions should not be collapsed into a single label such as ‘tissue bank’ or ‘361 product.’

For establishments manufacturing HCT/Ps regulated solely under section 361, Part 1271 applies whether or not the HCT/P enters interstate commerce, subject to the applicable exceptions. Keeping an activity within one state does not, by itself, remove it from this framework.

Under §1271.3(d), an HCT/P is an article containing or consisting of human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient. The definition includes examples such as bone, skin, cornea, peripheral- and cord-blood-derived hematopoietic stem/progenitor cells, and reproductive tissue. The intended destination and the exclusions both matter.

Two boundaries deserve particular attention. First, the blood exclusion is not an exclusion of every article derived from blood: the definition itself includes certain hematopoietic stem/progenitor cells. Second, the diagnostic-product exclusion does not mean that every device is outside the HCT/P framework. Section 1271.20 expressly includes a device route for HCT/Ps that do not meet the section 361-only criteria and lack an applicable establishment exception.

For the separate blood framework, see 21 CFR 606. Do not use a shared department, storage location or information system as a substitute for assessing the article itself.

Section 1271.10(a) uses an all-criteria test. Minimal manipulation alone is insufficient. The HCT/P must satisfy each of the four conditions below to be regulated solely under section 361 and Part 1271.

Minimal manipulation and homologous use are different tests

For structural tissue, minimal manipulation means processing that does not alter the original relevant characteristics relating to the tissue’s utility for reconstruction, repair or replacement. For cells or nonstructural tissues, processing must not alter their relevant biological characteristics. Homologous use, by contrast, concerns function: the HCT/P repairs, reconstructs, replaces or supplements the recipient’s cells or tissues while performing the same basic function or functions in the recipient as in the donor.

Objective intent is therefore part of the legal test, not merely an internal description of a process. As a review practice, compare the classification rationale with labeling, advertising and other statements about intended use. A processing assessment and a marketing review answer different parts of the test.

Read the fourth criterion as two alternatives

The first alternative requires both no systemic effect and no dependence on living-cell metabolic activity for the primary function. The second permits either characteristic when one of the three specified uses applies. Autologous use means returning cells or tissue to the individual from whom they were recovered; it does not dispense with the other three criteria.

An exclusion from the HCT/P definition, an exception for an establishment, and an exception from donor-eligibility requirements have different effects. Record the particular provision being relied upon rather than writing only ‘exempt.’

The six establishment provisions in §1271.15

• Nonclinical use: an establishment uses HCT/Ps solely for nonclinical scientific or educational purposes.
• Same surgical procedure: an establishment removes HCT/Ps from an individual and implants those HCT/Ps into the same individual during the same surgical procedure.
• Carrier activity: a carrier accepts, receives, carries or delivers HCT/Ps in the usual course of business as a carrier.
• Limited receipt or storage: an establishment only receives or stores HCT/Ps solely for implantation, transplantation, infusion or transfer within its facility, and does not recover, screen, test, process, label, package or distribute them.
• Immediate reproductive transfer: an establishment only recovers reproductive cells or tissue and immediately transfers them into a sexually intimate partner of the donor.
• Recovery-only individual under an arrangement: an individual working under contract, agreement or another arrangement with a registered establishment solely recovers cells or tissues and sends them to that establishment. Independent registration and listing are not required, but all other applicable Part 1271 requirements remain.

The same-surgical-procedure exception and autologous use are not interchangeable. The former includes a same-procedure condition in §1271.15(b); the latter describes return to the same individual and also appears in other provisions with different purposes.

For example, §1271.90(a) excepts autologous cells and tissues, and reproductive cells or tissue donated by a sexually intimate partner for reproductive use, from the specified donor-eligibility determination and screening/testing requirements. Its applicable labeling provisions still need attention. Consult donor eligibility for that separate assessment rather than treating a donor exception as proof of the product’s regulatory route.

Section 1271.20 applies when an establishment manufactures an HCT/P that does not meet §1271.10(a) and does not qualify for an exception in §1271.15. The resulting route is regulation as a drug, device and/or biological product under the Federal Food, Drug, and Cosmetic Act and/or section 351 of the Public Health Service Act, with applicable regulations.

That wording is broader than ‘every failed criterion requires a section 351 biologics license application.’ It preserves drug, device and biological-product possibilities, including overlapping authorities. This definition does not determine the route for a real product or elaborate the separate application requirements.

Part 1271 does not simply disappear on another route. Section 1271.1(b)(2) identifies registration and listing under Part 207 for drugs and/or biological products or Part 807 for devices, together with applicable Subpart C donor-eligibility and Subpart D CGTP procedures. Section 1271.150(d) explains that those procedures and the applicable manufacturing or quality-system regulations supplement rather than supersede each other unless expressly provided otherwise; in a conflict, the requirement more specifically applicable to the product supersedes the more general one.

‘Manufacture’ is broader than processing. Section 1271.3(e) includes recovery, processing, storage, labeling, packaging and distribution, as well as donor screening and testing. An establishment is generally a place of business under one management at one general physical location engaged in manufacture; the definition includes contract manufacturing facilities.

CGTP governs manufacturing methods, facilities and controls for preventing communicable-disease introduction, transmission or spread. Donor-eligibility provisions are set out separately in Subpart C. Under §1271.150(c)(1), an establishment performing only some operations complies with the requirements applicable to those operations.

• The contracted establishment is responsible for compliance with requirements applicable to the manufacturing step it performs.
• Before engaging another establishment for a manufacturing step, the engaging establishment must ensure applicable CGTP compliance. If information later suggests noncompliance, it must take reasonable steps to ensure compliance; if it determines that the establishment is not compliant, it must terminate the arrangement.
• The establishment that determines all release criteria are met and makes the HCT/P available for distribution must review manufacturing and tracking records for compliance with Subparts C and D and other applicable requirements—even if another establishment physically distributes the HCT/P.

A responsible person is someone authorized to perform designated functions for which that person is trained and qualified. As a practical responsibility map, distinguish the performer of each manufacturing step, the establishment managing the arrangement, and the establishment making the HCT/P available for distribution. A courier’s role should not be substituted for the release-establishment role.

An exemption request is not permission to begin

Section 1271.155 permits requests for exemptions from or alternatives to Subpart C or D requirements. The exemption or alternative must be granted before the establishment begins operating under its terms. An establishment using one must retain documentation of FDA’s grant and the date it began operating under it. A pending request does not satisfy that condition.

Once a donor-eligibility determination has been made, §1271.55(a) requires three things to accompany the HCT/P at all times: a distinct identification code affixed to its container, a statement that the donor was determined eligible or ineligible based on screening and testing, and a summary of the records used for that determination. The code relates the HCT/P to its donor and all records pertaining to it.

The identification-code privacy rule is qualified. Except for autologous donations, directed reproductive donations, or donations by first-degree or second-degree blood relatives, the code must not include an individual’s name, social security number or medical record number. Separately, §1271.55(c) requires that the accompanying records not contain the donor’s name or other personal information that might identify the donor. Do not collapse these two provisions into either ‘names are always permitted’ or ‘every code has an identical prohibition.’

The summary of records includes a listing and interpretation of communicable-disease test results and the name and address of the establishment that made the donor-eligibility determination. It is not merely a statement that a laboratory report exists.

Physical movement is not itself a release determination

Section 1271.3 defines ‘available for distribution’ as a determination that all release criteria have been met. ‘Distribution’ is conveyance or shipment of an HCT/P determined to meet those criteria, including entirely intrastate conveyance. Quarantine means storage or identification that prevents improper release, whether through a clearly identified physically separate area or other procedures such as automated designation.

As a record-design practice, keep donor determination, material location and release status distinct. A location change should not serve as evidence that release criteria were reviewed. For shipment and release procedures, use the HCT/P readiness guide, rather than extending these definitions into a blanket shipping rule.

Section 1271.270 requires records to be maintained concurrently with each required Subpart C or D step. They must be accurate, indelible and legible, identify the person performing the work and entry dates, and be detailed enough to provide a complete history linked to the particular HCT/P.

The records management system must support review before availability for distribution and subsequent follow-up evaluation or investigation. It also covers pertinent manufacturing records such as procedures and equipment logs. Where records occupy multiple locations, the system must enable their prompt identification, location and retrieval; the rule does not require every record to occupy one application.

The particular-HCT/P rule is not ‘administration or expiration, whichever is later.’ First determine whether the administration date is known. Only when it is unknown does the latest-of-distribution/disposition/expiration branch apply. Section 1271.55(d)(4) uses the same particular-HCT/P timing for its required donor records.

Permitted retention methods include electronic records, original paper records and true copies. Electronic records must be backed up, and equipment needed to make retained records available and legible must be readily available. Section 1271.270(e) also requires the name, address and responsibilities of establishments performing manufacturing steps for you to be maintained and available during inspection.

For implementation, organize a retention schedule by record category and triggering event rather than assigning one disposal date to an entire repository. A record-location map can identify the owner and retrieval route without requiring unnecessary duplication of sensitive donor information.

Section 1271.330 limits implementation of Subpart E to nonreproductive HCT/Ps described in §1271.10 and regulated solely under section 361 and Part 1271, and the establishments manufacturing them. HCT/Ps regulated as drugs or devices under the Act, or as biological products under section 351, are not subject to that subpart. Reporting scope therefore follows the product route and reproductive status, not simply the fact that human cells or tissue are involved.

The defined event categories also differ. An adverse reaction is a noxious and unintended response for which there is a reasonable possibility that the HCT/P caused the response. An HCT/P deviation includes departures from applicable regulations, standards or specifications related to communicable-disease prevention or contamination, and unexpected or unforeseeable events that may relate to transmission or contamination.

As an assessment practice, record the product route, event facts, affected HCT/Ps, manufacturing steps performed and distribution history before assigning reporting responsibility or a deadline. Keep the event description separate from the reportability conclusion. Do not import a blood-event clock merely because the same team or system also handles blood products.

Use the 21 CFR 1271 HCT/P readiness guide for operational treatment of receipt, quarantined predistribution shipment, release review, software assessment, tracking and reporting. For donor-specific handoffs and follow-up, use donor eligibility, lookback and deviation readiness. The framework here supplies the applicability questions; those guides are the place to develop the working records and procedures.